P

Protalix Biotherapeutics Inc
AMEX:PLX

Watchlist Manager
Protalix Biotherapeutics Inc
AMEX:PLX
Watchlist
Price: 2.055 USD -0.24% Market Closed
Market Cap: $165.3m

Net Margin

10.1%
Current
Improving
by 15%
vs 3-y average of -4.8%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
10.1%
=
Net Income
$6.3m
/
Revenue
$61.9m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
10.1%
=
Net Income
$6.3m
/
Revenue
$61.9m

Peer Comparison

Country Company Market Cap Net
Margin
US
Protalix Biotherapeutics Inc
AMEX:PLX
163.5m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
67th
Based on 15 072 companies
67th percentile
10.1%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Protalix Biotherapeutics Inc
Glance View

Market Cap
165.3m USD
Industry
Biotechnology

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. The company is headquartered in Hackensack, New Jersey and currently employs 193 full-time employees. The company went IPO on 2010-09-06. The firm is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Its ProCellEx platform is being used to manufacture approved and marketed product, Elelyso, for the treatment of Gaucher disease. The Company’s ProCellEx is its proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target pharmaceutical markets, including the product candidates, such as PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases, and others.

PLX Intrinsic Value
1.748 USD
Overvaluation 15%
Intrinsic Value
Price
P
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
10.1%
=
Net Income
$6.3m
/
Revenue
$61.9m
What is Protalix Biotherapeutics Inc's current Net Margin?

The current Net Margin for Protalix Biotherapeutics Inc is 10.1%, which is above its 3-year median of -4.8%.

How has Net Margin changed over time?

Over the last 3 years, Protalix Biotherapeutics Inc’s Net Margin has increased from -40.7% to 10.1%. During this period, it reached a low of -40.7% on Jun 30, 2022 and a high of 16.7% on Sep 30, 2023.

Back to Top